The popularity of copyright’s blockbuster initially drove a surge for pharma, but recent developments present a murky scenario for those considering a stake. Off-patent alternatives are reducing profits, and continued litigation add more difficulty to the equation. While some companies may still benefit from adjacent products, the general traject